Accueil Ernstrade Bourse Actualite Stock



Accelr8 Technology Corporation (Accelr8) focuses to develop and commercialize an integrated system to identify bacteria and their mechanisms of antibiotic resistance in critically ill patients. The Company’s OpTest portfolio of technologies (OpTest) provided it with a surface chemistry formulation and quantitative bio-analytical measurement instruments. It supplemented these assets to develop the BACcel technology platform for applications related to rapid identification of bacteria and their antibiotic resistance. The BACcel system applies its technology to eliminate time-consuming bacterial culturing, thus eliminating the source of delay with testing methods. Its technologies include Quantum Microbiology analytical methods, and its OptiChem surface coatings. The BACcel system includes a fixed instrument and single-use (disposable) test cassettes. Each cassette tests a single patient specimen and then must be discarded.
7000 Broadway Building 3 - 307
Denver, CO 80221
United States -
+1-303-8638088 (Phone)
+1-303-8631218 (Fax)  

Copyright  2011